Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences.
Albumedix Ltd ('Albumedix'), Nottingham, United Kingdom, now part of the global life science group Sartorius, and Heartseed Inc ('Heartseed'), Tokyo, Japan, Tuesday 14th March 2023, announce that Recombumin® is a critical component of Heartseed's HS-001, an investigational cardiac remuscularization cell therapy which has commenced first in human dosing.
Albumedix is a recognized global leader in the supply and development of high-quality recombinant human albumin solutions, specialising in the enablement of advanced therapies and next-generation biopharmaceuticals. Collaboration between Albumedix and Heartseed supported the strategic deployment of Recombumin as an integral excipient in the HS-001 therapy. Recombumin's functional benefits are also leveraged to support the formation of cardiomyocyte spheres and to offer enhanced cell viability during transportation and distribution, which ultimately will support implementation of the treatment in the clinic.
Albumedix and Heartseed's partnership on this project manifests Albumedix' commitment to better health through its enablement of advanced therapies. The high potential of Heartseed's novel HS-001 cell therapy has been recognised through several awards that Heartseed have received in recognition of their innovation.
Albumedix' Chief Executive Officer, Mr Jonas Skjødt Møller, reflecting on the announcement said: "evolution is a hallmark of the advanced therapy space, however, Heartseed's HS-001 therapy could mark a potential point of revolution. We are exceptionally excited to see the successful outcome of our close collaboration, which sees Recombumin used as a safe, consistent, and vital component of HS-001's development. We are keen to empower excellence in the creation of truly transformative biopharmaceuticals through our recombinant human albumin products, and this milestone showcases the power of our solutions, and our customers' trust in Albumedix".
Heartseed's CMO, Dr Takehiko Kaneko, added: "Heartseed is exceptionally proud of the milestone that the commencement of our in-human trial marks for HS-001. Building on the work of our founder and CEO, Dr Keiichi Fukuda, if successful, our novel cardiac remuscularization therapy stands to revolutionize cardiac medicine. Albumedix' near four decades of experience with recombinant albumin, and their Recombumin portfolio, played an important role in supporting the formulation and manufacture of this novel therapy. Our partnership with Albumedix helps us towards our goal of advancing standards of care for patients with heart failure."
Based in Nottingham, United Kingdom, Albumedix' partnership with Heartseed spotlights the global scale of Albumedix' operations and underlines the importance of international scientific collaboration in pursuit of better health.
The Recombumin® product portfolio consists of commercially available, high-quality, animal and human-origin-free recombinant human albumins. Recombumin is a multi-functional excipient, ancillary and raw material, and its stabilizing properties have been validated through long-established use in multiple marketed life science products. Albumedix' highly pure, safe, and consistent recombinant albumins support advanced therapies at every stage of their journey from research and development to in-human application.
Albumedix, now part of the life sciences group Sartorius, is an innovation-focused biotechnology company, well recognized as a leader in albumin-enabled solutions. With its mission dedicated to better health, over its near four decades of commitment, Albumedix has supported its partners to deliver safe doses globally, in both clinical development phase and marketed therapeutics, to millions of patients. Albumedix' portfolio of solutions includes the world's only USP-NF-compliant recombinant human albumin (Recombumin®); client-centric services, and proprietary drug-enhancing technology (Veltis®).
Established in 2015, Heartseed has committed its knowledge and resources to realising a regenerative therapy capable of supporting patients suffering from heart failure. Heartseed's HS-001 therapy sees cardiomyocytes derived from allogeneic iPS cells directly transplanted into cardiac tissue. Dr Keiichi Fukuda MD PhD FACC first reported on generating cardiomyocytes from iPS cells in 1999; the progression of Heartseed's treatment HS-001 to a human trial marks a new phase in Heartseed's journey and brings the organization closer to changing the world with regenerative medicines.